27 completed, 9 terminated, 8 recruiting, 6 not yet recruiting. 58 Phase 2, 14 Phase 1, 6 Phase 3.
Follow Capsules: new trials by email Literature Review of Capsules trials Research Report on Capsules
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nicotinamide Riboside Supplementation in Chronic Kidney Disease Nicotinamide Riboside (NR), Matched Placebo (Capsules) - Chronic Kidney Disease | Phase 2 | Not yet recruiting | University of California, San Diego | 30 | 2027-01-15 | 2026-11-12 |
| Verapamil In Preclinical Type 1 Diabetes Verapamil 120 Mg/24 Hours Oral Capsule, Extended Release, Placebo, blood sampling - Type 1 Diabetes | Phase 2 / Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 50 | 2027-01-01 | 2026-10-22 |
| LiO-AD: Lithium Orotate in Alzheimers Disease Feasibility, Biomarker Engagement, and Clinical Response Lithium orotate, Matched Placebo (Capsules) - Alzheimer s Disease | Phase 1 / Phase 2 | Not yet recruiting | Johns Hopkins University | 40 | 2026-12-01 | 2026-10-07 |
| Modulation of Stem Cell Differentiation in Individuals With High Risk Clonal Haematopoiesis Oral Decitabine and Tetrahydrouridine, Matched Placebo (Capsules) - Clonal Cytopenia of Uncertain Significance, CCUS Clonal Cytopenia of Undetermined Significance | Phase 2 | Not yet recruiting | Clinical Hub for Interventional Research (CHOIR) | 80 | 2026-12-01 | 2026-11-04 |
| Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE) Microbiota transplant therapy (MTT) capsules, Placebo capsule - Hepatic Encephalopathy, Cirrhosis | Phase 2 | Not yet recruiting | VA Office of Research and Development | 162 | 2026-10-30 | 2026-04-14 |
| Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT) ATV-1601, Placebo - Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease | Phase 1 / Phase 2 | Recruiting | Atavistik Bio, Inc | 100 | 2026-07-27 | 2026-11-06 |
| Fecal Microbiota Transplantation for Elderly Patients With HFpEF: A Randomized Controlled Trial Fecal Microbiota Transplantation (FMT) Capsules, Placebo capsules - Heart Failure With Preserved Ejection Fraction (HFPEF), Chronic Heart Failure | Phase 1 / Phase 2 | Not yet recruiting | The First Affiliated Hospital of Air Force Medicial University | 50 | 2026-06-01 | 2026-06-05 |
| Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency Disorder Lumateperone (ITI-007), Placebo Tablet or Capsule - Stuttering, Adult | Phase 2 | Recruiting | CSTrials Inc. | 24 | 2026-04-18 | 2026-07-29 |
| Efficacy and Safety of TRD205 Tablets for Postoperative Analgesia in Unilateral Total Hip Arthroplasty (Phase IIb) TRD205 Tablets, oral; 400 mg initial dose, then 200 mg q12h for 3 doses; total 4 doses, TRD205 Tablets, oral; 800 mg initial dose, then 400 mg q12h; total 4 doses, TRD205 Tablets, oral; 1200 mg initial dose, then 600 mg q12h; total 4 doses - Postoperative Analgesia After Unilateral Hip Arthroplasty | Phase 2 | Recruiting | Beijing Tide Pharmaceutical Co., Ltd | 200 | 2026-03-18 | 2026-04-22 |
| Study of DONQ52 in Active Celiac Disease Placebo DONQ52, Simulated Inadvertent Gluten Exposure (SIGE) capsule, DONQ52 - Celiac Disease | Phase 2 | Recruiting | Chugai Pharmaceutical | 92 | 2025-12-16 | 2026-08-14 |
| Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome Quercetin, Alpha Lipoic Acid 600 MG Oral Tablet, MetFORMIN 500 Mg Oral Tablet - PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries | Phase 2 | Recruiting | Al-Mustansiriyah University | 150 | 2025-09-20 | 2025-09-19 |
| Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis Budesonide MMX®, Budesonide controlled ileal release (CR) capsules - Microscopic Colitis | Phase 2 | Active not recruiting | University of Calgary | 80 | 2024-03-21 | 2026-10-21 |
| Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2). LQT-1213, Placebo, Dofetilide 250 μg Cap - Long QT Syndrome | Phase 1 / Phase 2 | Terminated | Thryv Therapeutics, Inc. | 42 | 2023-03-12 | 2025-07-24 |
| Effect of Supplementation With Anthocyanins on Iron Metabolism in Female Swimmers Black chokeberry extract in capsules with 18% standardization of the anthocyanins content, Chokeberry fiber in capsules - Iron Deficiencies, Inflammation | Phase 1 / Phase 2 | Completed | Poznan University of Physical Education | 22 | 2023-03-01 | 2024-07-03 |
| RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial Oral Restorative Microbiota Therapy (RMT) Capsules, Durvalumab 1500 mg IV, Cisplatin/pemetrexed or Carboplatin/pemetrexed - Adenocarcinoma of Lung, Lung Cancer | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 82 | 2022-11-30 | 2026-09-17 |
| Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease Intestinal Microbiota Transplant (IMT) Capsules, Placebo Capsules - Liver Disease; Alcohol-Related, Cirrhosis | Phase 1 / Phase 2 | Active not recruiting | Virginia Commonwealth University | 80 | 2022-11-21 | 2026-08-24 |
| The CANabidiol Use for RElief of Short Term Insomnia 50 mg Cannabidiol (CBD), Placebo, 100 mg Cannabidiol (CBD) - Sleep Disturbance, Insomnia | Phase 2 | Completed | Bod Australia | 208 | 2022-05-01 | 2023-08-16 |
| Noise-Induced Hearing Loss-Acute Exposure Treatment (UA) Zonisamide 100Mg Cap, Placebo - Hearing Loss, Noise-Induced | Phase 2 | Terminated | Washington University School of Medicine | 3 | 2021-11-10 | 2026-02-13 |
| Clinical Trial for Oral Formula of Vanillin and Wheat Germ Oil for Treatment of Mild and Moderate COVID-19 Viral Disease Oral Capsule - Mild-to-moderate COVID-19 | Phase 2 / Phase 3 | Unknown | Alexandria University | 120 | 2021-11-01 | 2022-01-31 |
| Noise-Induced Hearing Loss-Acute Exposure Treatment Zonisamide 100Mg Cap, Placebo - Hearing Loss, Noise-Induced | Phase 2 | Terminated | Washington University School of Medicine | 24 | 2021-10-04 | 2025-01-15 |
Showing 20 of 58. Sign in to see all of them.
Fibrosis (3) · Alzheimer Disease (2) · Attention Deficit Disorder with Hyperactivity (2) · COVID-19 (2) · Diabetes Mellitus, Type 1 (2) · Diabetes Mellitus, Type 2 (2) · Fatigue (2) · Hearing Loss, Noise-Induced (2) · Inflammation (2) · Liver Diseases (2) · Obesity (2) · Renal Insufficiency, Chronic (2) · Telangiectasia, Hereditary Hemorrhagic (2) · Adenocarcinoma of Lung (1) · Alcoholism (1)
Fudan University (2) · Novartis Pharmaceuticals (2) · VA Office of Research and Development (2) · Washington University School of Medicine (2) · Abbott (1) · Aimmune Therapeutics, Inc. (1) · Al-Mustansiriyah University (1) · Alexandria University (1) · All India Institute of Medical Sciences, Bhubaneswar (1) · Andrew Slivka (1) · Anu Sharma (1) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · Atavistik Bio, Inc (1) · Beijing Tide Pharmaceutical Co., Ltd (1)
United States (30) · Canada (5) · France (5) · United Kingdom (5) · Australia (4) · China (4) · Germany (4) · South Korea (4) · Spain (4) · Belgium (3) · Italy (3) · Netherlands (3) · Poland (3) · Taiwan (3) · India (2)
Craig A Buchman, MD, FACS (2) · Alfonso Galderisi, Phd (1) · Anu Sharma, MD (1) · Armin Ahmadi, PhD (1) · Chang-Chieh Wu, MD (1) · Christopher Ma, MD MPH (1) · Christopher Morrow, MD, MHS (1) · Daryl I Shorter, MD (1) · Dennis Andress, MD (1) · Dwight D Koeberl, MD, PhD (1)
PMID 19923168, PMID 20620737, PMID 21055801, PMID 21079055, PMID 22212857, PMID 22387529, PMID 22795280, PMID 23391616, PMID 23787544, PMID 24840045, PMID 28738099, PMID 30025991, PMID 30869182, PMID 30937899, PMID 31369655, PMID 31740368, PMID 32863171, PMID 33197289, PMID 33568226, PMID 33642973, PMID 34389504, PMID 34814185, PMID 35045888, PMID 35096250, PMID 35127778, PMID 35798516, PMID 36344987, PMID 36647114, PMID 36725099, PMID 39131144, PMID 39307154, PMID 39929221, PMID 41057918, PMID 42518155, PMID 42564695
1IK2CX000946-01 (1), 2018 (1), 2023 (1), 2025 (1), K01DK147652 (1), R01AA029398 (1), ZIAHD000641-23 (1)